dan 2163 has been researched along with scopolamine hydrobromide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Amad, A; Cuvelier, E; Décaudin, B; Fovet, T; Gressier, B; Simon, N | 1 |
1 review(s) available for dan 2163 and scopolamine hydrobromide
| Article | Year |
|---|---|
[Treatment options for drug-induced sialorrhea: Prescribing guidelines].
Topics: Amisulpride; Antipsychotic Agents; Cholinergic Antagonists; Clozapine; Female; Humans; Male; Quality of Life; Scopolamine; Sialorrhea | 2022 |
1 other study(ies) available for dan 2163 and scopolamine hydrobromide
| Article | Year |
|---|---|
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |